What is the foundational importance of the LEADER trial and what makes it different and, perhaps, more significant than previous trials evaluating strategies for CV risk reduction in T2D?

What is the foundational importance of the LEADER trial and what makes it different and, perhaps, more significant than previous trials evaluating strategies for CV risk reduction in T2D?

What is the foundational importance of the LEADER trial and what makes it different and, perhaps, more significant than previous trials evaluating strategies for CV risk reduction in T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center Past President, Science and Medicine American Diabetes Association